Lixte Biotechnology Faces Delisting Concerns
Ticker: LIXT · Form: 8-K · Filed: Oct 23, 2024 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | 8-K |
| Filed Date | Oct 23, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $2,500,000, $4,000,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, biotechnology
Related Tickers: LIXT
TL;DR
LIXT might get delisted - stock could tank.
AI Summary
Lixte Biotechnology Holdings, Inc. filed an 8-K on October 23, 2024, reporting a notice of delisting or failure to meet continued listing standards as of October 21, 2024. The company, incorporated in Delaware, is based in Pasadena, California, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates potential delisting from a stock exchange, which could significantly impact the company's liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to trade on an exchange, posing a significant risk to its operations and investors.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer
- October 21, 2024 (date) — Date of earliest event reported
- October 23, 2024 (date) — Date of report
- 001-39717 (company) — Commission File Number
- 20-2903526 (company) — IRS Employer Identification No.
- 680 East Colorado Boulevard , Suite 180 Pasadena , California 91101 (company) — Address of principal executive offices
- (631) 830-7092 (company) — Registrant’s telephone number
FAQ
What specific listing rule or standard has Lixte Biotechnology Holdings, Inc. failed to meet?
The filing does not specify the exact listing rule or standard that has not been met, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is October 21, 2024.
What is the Commission File Number for Lixte Biotechnology Holdings, Inc.?
The Commission File Number for Lixte Biotechnology Holdings, Inc. is 001-39717.
In which state was Lixte Biotechnology Holdings, Inc. incorporated?
Lixte Biotechnology Holdings, Inc. was incorporated in Delaware.
What is the primary business address of Lixte Biotechnology Holdings, Inc.?
The primary business address is 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.
Filing Stats: 608 words · 2 min read · ~2 pages · Grade level 14.7 · Accepted 2024-10-23 08:30:14
Key Financial Figures
- $2,500,000 — mum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Cap
- $4,000,000 — SEC on October 22, 2024 to raise up to $4,000,000 of equity capital. On October 21, 202
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-042172.txt ( ) — 251KB
- lixt-20241021.xsd (EX-101.SCH) — 3KB
- lixt-20241021_def.xml (EX-101.DEF) — 29KB
- lixt-20241021_lab.xml (EX-101.LAB) — 36KB
- lixt-20241021_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 23, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan Chief Executive Officer